Description

Delparantag (PMX-60056) is a salicylamide derivative and an effective unfractionated heparin (UFH) and low molecular weight heparin (LMWH) reversing agent. Delparantag shows ability to neutralize the anticoagulation and bleeding effects of UFH and LMWH[1][2].—Neuroscience-Neuromodulation–C56H79N13O12—-[1]Mahan CE. A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents. J Thromb Thrombolysis. 2014 Apr;37(3):271-8.|[2]Kuziej J, et al. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative. Clin Appl Thromb Hemost. 2010 Aug;16(4):377-86.–872454-31-4–1126.31—-O=C(C(C=C1NC([C@H](CCCCN)NC(C(C=C2NC([C@@H](N)CCCCN)=O)=C(C=C2)OC)=O)=O)=C(C=C1)OC)N[C@@H](CCCCN)C(NC(C=C3)=CC(C(N[C@@H](CCCCN)C(NC(C=C4)=CC(C(N)=O)=C4OC)=O)=O)=C3OC)=O–Cardiovascular Disease–10 mM in DMSO–Factor Xa—-Metabolic Enzyme/Protease–Peptides